Florida lawmakers look to cap biotech investment

Over the past two years, Florida's Innovation Incentive program has pumped all of its money--hundreds of millions of dollars--to persuade a group of prestigious research centers to set up operations in the state. Supporters say that it is one of the most successful economic incentive programs in biotech (and made FierceBiotech's Top 5 biotech economic development list two years running).

But some lawmakers say the state shouldn't be putting all its investment eggs in one biotech basket. A new bill would limit any one industry to half of the funds available and give the state a share of any royalties from commercialization efforts. Palm Beach officials, though, say that a move like that would limit its efforts to attract more biomedical research to the area.

''We are concerned that decreased funding certainly would take away from the momentum that the state has developed in attracting the bioscience industry,'' Kelly Smallridge, president of the Business Development Board of Palm Beach County, told the Palm Beach Post. "There are still a number of sizable institutions considering our location.

- read the article from the Palm Beach Post

Related Articles:
Florida--Top Five Regions Targeting Biotech Companies, 2008. Report
Max Planck Society eyes Florida research center. Report
Florida moves up the charts in tech spin-offs. Report
Florida gets an honorable mention, with a warning. Report
Can Florida woo biotechs? Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.